There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin, a drug-antibody conjugate approved for the treatment of lymphoma and targeted to the protein CD30 molecule expressed on activated immune cells There is evidence for CD30 involvement in SSc. This study represents the first step in determining safety and tolerability of brentuximab vedotin in SSc.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.
Timeframe: Baseline through end of study (48 weeks for participants who complete the study)
Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48.
Timeframe: Baseline through end of study (48 weeks)